DGIdb - SULFASALAZINE Drug Record

SULFASALAZINE chembl:CHEMBL421 ApprovedImmunotherapy

Alternate Names:

SULFASALAZINE
NSC-667219
SALAZOPYRIN-EN
SALAZOSULFAPYRIDINE
AZULFIDINE EN
AZULFIDINE EN-TABS
SAS-500
COLIZINE
SALAZOPYRIN
S.A.S.
SULPHASALAZINE
UCINE
AZULFIDINE
S.A.S.-500
SALAZOPYRIN E.C.
NSC-203730
SALICYLAZOSULFAPYRIDINE
SALAZOSULFAPYRIDINUM
SULFASALAZINA
SALAZOPYRIN®
2-HYDROXY-5-[4-(PYRIDIN-2-YLSULFAMOYL)-PHENYLAZO]-BENZOIC ACID
AZULFIDINE®
5-(P-(2-PYRIDYLSULFAMYL)PHENYLAZO)SALICYLIC ACID
SULFASALAZINUM
AZOPYRIN
SULFASALAZIN
4-(PYRIDYL-2-AMIDOSULFONYL)-3'-CARBOXY-4'-HYDROXYAZOBENZENE
5-(4-(2-PYRIDYLSULFAMOYL)PHENYLAZO)-2-HYDROXYBENZOIC ACID
2-HYDROXY-5-((4-((2-PYRIDINYLAMINO)SULFONYL)PHENYL)AZO)BENZOIC ACID
SALAZOSULFAPIRIDINA
5-((P-(2-PYRIDYLSULFAMOYL)PHENYL)AZO)SALICYLIC ACID
SALAZOPYRIDIN®
rxcui:9524
pubchem.compound:5353980
chemidplus:599-79-1
chembl:CHEMBL421
drugbank:00795

Drug Info:

FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antiinflammatory agent,DMARD
Drug Class	antirheumatic agents
Year of Approval	1950
Drug Class	anti-inflammatory agents, non-steroidal
Drug Categories	agents causing hyperkalemia
Drug Categories	agents that produce hypertension
Drug Categories	aminosalicylate
Drug Categories	anti-inflammatory agents, non-steroidal (non-selective)
Drug Categories	genito urinary system and sex hormones
Drug Categories	gynecological antiinfectives and antiseptics
Drug Categories	immunosuppressive agents
Drug Categories	methemoglobinemia associated agents
Drug Categories	nephrotoxic agents
Drug Categories	non cox-2 selective nsaids
Drug Categories	oatp1b1/slco1b1 inhibitors
Drug Categories	oatp1b3 inhibitors
Drug Categories	salicylates

(7 More Sources)

Publications:

Schwahn B et al., 2001, Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences., Am J Pharmacogenomics
Matasić et al., 2001, Maturation of human dendritic cells as sulfasalazine target., Croat. Med. J.
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Faison et al., 1992, Sulfasalazine inhibits lyso-PAF: acetyl-COA acetyltransferase., Prostaglandins
Allgayer et al., 1984, Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine., Eur. J. Clin. Pharmacol.
Nielsen et al., 1987, Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid., Dig. Dis. Sci.
Sircar et al., 1983, Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis., Biochem. Pharmacol.
Allgayer, 2003, Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease., Aliment. Pharmacol. Ther.
Distrutti et al., 2006, 5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity., J. Pharmacol. Exp. Ther.
Mifflin et al., 2004, Aspirin-mediated COX-2 transcript stabilization via sustained p38 activation in human intestinal myofibroblasts., Mol. Pharmacol.
Generini et al., Therapy of spondylarthropathy in inflammatory bowel disease., Clin. Exp. Rheumatol.
Pruzanski et al., 1997, Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity., Biochem. Pharmacol.
Cipolla et al., 2002, Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives., Pharmacol. Res.
Kashihara Y et al., 2017, Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP., J Pharm Sci
Gotanda K et al., 2015, Sulfasalazine disposition in a subject with 376C>T (nonsense mutation) and 421C>A variants in the ABCG2 gene., Br J Clin Pharmacol
Wiese MD et al., 2014, Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis., Pharmacogenomics J
Yamasaki Y et al., 2008, Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans., Clin Pharmacol Ther
Selhub et al., 1978, Inhibition of folate enzymes by sulfasalazine., J. Clin. Invest.
Stenson et al., 1983, Inhibition of platelet thromboxane synthetase by sulfasalazine., Biochem. Pharmacol.
Cohen SM et al., 1968, Ulcerative colitis and erythrocyte G6PD deficiency. Salicylazosulfapyridine-provoked hemolysis., JAMA
Gout et al., 2001, Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug., Leukemia
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Weber et al., 2000, Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta., Gastroenterology
Morabito et al., 1998, Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides., J. Clin. Invest.
de Bruin et al., 2004, Sulfasalazine down-regulates the expression of the angiogenic factors platelet-derived endothelial cell growth factor/thymidine phosphorylase and interleukin-8 in human monocytic-macrophage THP1 and U937 cells., Mol. Pharmacol.
James HM et al., 2008, Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis., J Rheumatol
Yang F et al., 2014, HLA-B*13:01 is associated with salazosulfapyridine-induced drug rash with eosinophilia and systemic symptoms in Chinese Han population., Pharmacogenomics
Rousseaux et al., 2005, Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma., J. Exp. Med.
Linard et al., 2008, Reduction of peroxisome proliferation-activated receptor gamma expression by gamma-irradiation as a mechanism contributing to inflammatory response in rat colon: modulation by the 5-aminosalicylic acid agonist., J. Pharmacol. Exp. Ther.
Desreumaux et al., 2006, Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence., Aliment. Pharmacol. Ther.
Schwab et al., 2008, PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells., Carcinogenesis

SULFASALAZINE CD83

Interaction Score: 3.92

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11471196

Sources:
NCI
SULFASALAZINE ACAT1

Interaction Score: 3.92

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name sulfasalazine,Azulfidine, Salazopyrin

Novel drug target Established target

PMIDs:
17016423 17139284 1357724

Sources:
DrugBank TdgClinicalTrial TEND
SULFASALAZINE SLC7A11

Interaction Score: 0.84

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
11587223 11752352

Sources:
DrugBank
SULFASALAZINE TBXAS1

Interaction Score: 0.65

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

PMIDs:
6135423

Sources:
DrugBank
SULFASALAZINE TYMP

Interaction Score: 0.56

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15269287

Sources:
NCI
SULFASALAZINE SLC46A1

Interaction Score: 0.49

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
None found

Sources:
GuideToPharmacology
SULFASALAZINE CHUK

Interaction Score: 0.49

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
12950415 11054378

Sources:
DrugBank
SULFASALAZINE TYMSOS

Interaction Score: 0.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18322994

Sources:
PharmGKB
SULFASALAZINE NT5E

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9435300

Sources:
NCI
SULFASALAZINE ALOX5

Interaction Score: 0.26

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Arachidonate 5-lipoxygenase inhibitor

PMIDs:
6428914 2882965 6131674

Sources:
DrugBank ChemblInteractions
SULFASALAZINE IKBKB

Interaction Score: 0.23

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
12950415 11054378

Sources:
DrugBank
SULFASALAZINE ABCG2

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28322941 25872459 24394199 18167504

Sources:
PharmGKB TTD
SULFASALAZINE HLA-B

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25303297

Sources:
PharmGKB
SULFASALAZINE MTHFR

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12083967

Sources:
PharmGKB
SULFASALAZINE PTGS2

Interaction Score: 0.13

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name sulfasalazine,Azulfidine, Salazopyrin

Novel drug target Established target

Mechanism of Interaction Cyclooxygenase inhibitor

PMIDs:
16855178 14742690 12463455 9256165 12208114

Sources:
DrugBank TdgClinicalTrial ChemblInteractions
SULFASALAZINE PLA2G1B

Interaction Score: 0.13

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

PMIDs:
9256165

Sources:
DrugBank
SULFASALAZINE DHFR

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22555

Sources:
NCI
SULFASALAZINE TYMS

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18322994

Sources:
PharmGKB
SULFASALAZINE G6PD

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
4386139

Sources:
PharmGKB FDA
SULFASALAZINE PTGS1

Interaction Score: 0.07

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Cyclooxygenase inhibitor

Novel drug target Established target

PMIDs:
12950415

Sources:
DrugBank TdgClinicalTrial ChemblInteractions
SULFASALAZINE PPARG

Interaction Score: 0.07

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name sulfasalazine,Azulfidine, Salazopyrin

Novel drug target Established target

PMIDs:
15824083 18077625 16939423 18544567

Sources:
DrugBank TdgClinicalTrial
SULFASALAZINE NFKB2

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
SULFASALAZINE HIF1A

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SULFASALAZINE CYP2C9

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
SULFASALAZINE HPGD

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SULFASALAZINE CYP1A2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
SULFASALAZINE CYP2D6

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
SULFASALAZINE MAPT

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SULFASALAZINE CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC

DrugBank: DB00795

Version: 5.1.7

Alternate Names:

SULFASALAZINE DrugBank Drug Name

599-79-1 CAS Number

Apo Sulfasalazine Tab 500mg Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories agents causing hyperkalemia

Publications:

Nielsen et al., 1987, Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid., Dig. Dis. Sci.

Sircar et al., 1983, Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis., Biochem. Pharmacol.

Allgayer et al., 1984, Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine., Eur. J. Clin. Pharmacol.

TEND: SULFASALAZINE
- Version: 01-August-2011
Alternate Names:

SULFASALAZINE Primary Drug Name

Drug Info:

Drug Class anti-inflammatory agents, non-steroidal

Year of Approval 1950

Drug Class antirheumatic agents

Publications:
TdgClinicalTrial: SULFASALAZINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antiinflammatory agent,DMARD

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: SULFASALAZINE

Version: 14-September-2017

Alternate Names:

C29469 NCI drug code

Drug Info:

Publications:

Matasić et al., 2001, Maturation of human dendritic cells as sulfasalazine target., Croat. Med. J.

de Bruin et al., 2004, Sulfasalazine down-regulates the expression of the angiogenic factors platelet-derived endothelial cell growth factor/thymidine phosphorylase and interleukin-8 in human monocytic-macrophage THP1 and U937 cells., Mol. Pharmacol.

Selhub et al., 1978, Inhibition of folate enzymes by sulfasalazine., J. Clin. Invest.

DTC: SULFASALAZINE
- Version: 02-September-2020
Alternate Names:

CHEMBL421 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

PharmGKB: sulfasalazine

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Schwahn B et al., 2001, Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences., Am J Pharmacogenomics

Cohen SM et al., 1968, Ulcerative colitis and erythrocyte G6PD deficiency. Salicylazosulfapyridine-provoked hemolysis., JAMA

Yamasaki Y et al., 2008, Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans., Clin Pharmacol Ther

TTD: Sulfasalazine
- Version: 2020.06.01
Alternate Names:

D02ZTJ TTD Drug ID

Drug Info:

Publications:
GuideToPharmacology: 178101542
- Version: 29-September-2020
Alternate Names:

SULFASALAZINE GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL421
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
FDA: Sulfasalazine
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL421
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Trial Name	sulfasalazine,Azulfidine, Salazopyrin
Novel drug target	Established target

Specific Action of the Ligand	Inhibition
Endogenous Drug?	False

Direct Interaction	yes
Mechanism of Interaction	Arachidonate 5-lipoxygenase inhibitor

Direct Interaction	yes
Mechanism of Interaction	Cyclooxygenase inhibitor
Novel drug target	Established target

SULFASALAZINE	DrugBank Drug Name
599-79-1	CAS Number
Apo Sulfasalazine Tab 500mg	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Categories	agents causing hyperkalemia

SULFASALAZINE Drug Record

SULFASALAZINE chembl:CHEMBL421 ApprovedImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11471196

Sources: NCI

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name sulfasalazine,Azulfidine, Salazopyrin Novel drug target Established target

PMIDs: 17016423 17139284 1357724

Sources: DrugBank TdgClinicalTrial TEND

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 11587223 11752352

Sources: DrugBank

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info:

PMIDs: 6135423

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15269287

Sources: NCI

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False

PMIDs: None found

Sources: GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 12950415 11054378

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18322994

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9435300

Sources: NCI

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Arachidonate 5-lipoxygenase inhibitor

PMIDs: 6428914 2882965 6131674

Sources: DrugBank ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 12950415 11054378

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28322941 25872459 24394199 18167504

Sources: PharmGKB TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25303297

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12083967

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name sulfasalazine,Azulfidine, Salazopyrin Novel drug target Established target Mechanism of Interaction Cyclooxygenase inhibitor

PMIDs: 16855178 14742690 12463455 9256165 12208114

Sources: DrugBank TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info:

PMIDs: 9256165

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22555

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18322994

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 4386139

Interaction Types & Directionality:

n/a

PMIDs:
11471196

Sources:
NCI

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name sulfasalazine,Azulfidine, Salazopyrin

Novel drug target Established target

PMIDs:
17016423 17139284 1357724

Sources:
DrugBank TdgClinicalTrial TEND

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
11587223 11752352

Sources:
DrugBank

Interaction Types & Directionality:

antagonist (inhibitory)

PMIDs:
6135423

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
15269287

Sources:
NCI

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
None found

Sources:
GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
12950415 11054378

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
18322994

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
9435300

Sources:
NCI

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Arachidonate 5-lipoxygenase inhibitor

PMIDs:
6428914 2882965 6131674

Sources:
DrugBank ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
12950415 11054378

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
28322941 25872459 24394199 18167504

Sources:
PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
25303297

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
12083967

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name sulfasalazine,Azulfidine, Salazopyrin

Novel drug target Established target

Mechanism of Interaction Cyclooxygenase inhibitor

PMIDs:
16855178 14742690 12463455 9256165 12208114

Sources:
DrugBank TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

antagonist (inhibitory)

PMIDs:
9256165

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
22555

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
18322994

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
4386139

Sources:
PharmGKB FDA

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Cyclooxygenase inhibitor

Novel drug target Established target

PMIDs:
12950415

Sources:
DrugBank TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name sulfasalazine,Azulfidine, Salazopyrin

Novel drug target Established target

PMIDs:
15824083 18077625 16939423 18544567

Sources:
DrugBank TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found